Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Biologic to Acquire TianXinFu, a Device Company, in $536 Million Deal

publication date: Oct 12, 2017

China Biologic Products, a plasma company headquartered in Beijing, will acquire an 80% interest in TianXinFu (Beijing) Medical Appliance in an all-stock deal worth $536 million. According to China Biologic, TianXinFu is China's largest maker of biomaterial scaffolds, which aid new tissue regeneration and organ repair. China Biologic will issue 5.5 million shares to PW Medtech to pay for the acquisition. Its stock price fell almost 15% after the deal was announced. More details...

Stock Symbol: (NSDQ: CBPO) (HK: 1358)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.